Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01285050 · ClinicalTrials.gov registry record · Phase 4
Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds
A Phase 4 study, sponsored by Johns Hopkins University.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
NCT01285050: Completed Phase 4 study, sponsored by Johns Hopkins University.
NCT01285050 is a Phase 4 study that has completed, run by Johns Hopkins University. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01285050, a Phase 4 study, has completed, sponsored by Johns Hopkins University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
Study Summary
The chief purpose of this research is to evaluate interferon alpha sensitivity and cell type specific levels of interferon receptor and interferon stimulated genes and proteins in HIV/ HCV (hepatitis C virus) coinfected persons before and after administration of HIV medications (antiretroviral therapy).
Interventions
- DRUG Emtricitabine and tenofovir disoproxil fumarate
- DRUG raltegravir
- DRUG Antiretroviral therapy (ART)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2011-01 |
| Est. Completion | 2015-04 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01285050
The ClinicalTrials.gov registry entry for NCT01285050 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Emtricitabine and tenofovir disoproxil fumarate is the first listed.
NCT01285050 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01285050 about?
NCT01285050 is a clinical study titled "Interferon Alfa Sensitivity in HIV/HCV Persons Before and After HIV Meds". The chief purpose of this research is to evaluate interferon alpha sensitivity and cell type specific levels of interferon receptor and interferon stimulated genes and proteins in HIV/ HCV (hepatitis C virus) coinfected persons before and after administration of HIV medications (antiretroviral thera...
What is the current status of trial NCT01285050?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2011-01. Estimated completion is 2015-04.
What interventions are being tested in trial NCT01285050?
The interventions under investigation include: Emtricitabine and tenofovir disoproxil fumarate (DRUG), raltegravir (DRUG), Antiretroviral therapy (ART) (DRUG).
Who is sponsoring clinical trial NCT01285050?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.